Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H18N4O5S2.2H2O |
| Molecular Weight | 494.541 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)CC4=CC=CS4)C3=O)C([O-])=O)C=C1
InChI
InChIKey=MJKBYXGLUCGDRX-LEVQAPRMSA-N
InChI=1S/C20H18N4O5S2.2H2O/c21-17(26)11-3-5-23(6-4-11)9-12-10-31-19-15(18(27)24(19)16(12)20(28)29)22-14(25)8-13-2-1-7-30-13;;/h1-7,15,19H,8-10H2,(H3-,21,22,25,26,28,29);2*1H2/t15-,19-;;/m1../s1
Cefalonium is a 1st generation cephalosporin with a broad spectrum of actvity against Gram-positive and Gram-negative bacterias. The drug inhibits the bacterial cell wall synthesis by binding to penicillin binding proteins. Cefalonium is approved for routine dry cow therapy to treat existing sub-clinical infections and to prevent new infections which occur during the dry period.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | CEPRAVIN Approved UseIn conjunction with, proper management of the cow during drying-off and over the dry period, correct administration of Cepravin Dry Cow at drying off: (1) Reduces new infections at drying off and in the dry period; (2) Treats subclinical mastitis that may be present at drying off; (3) Helps reduce SCC's and mastitis in the subsequent lactation. |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 68 | 70 |
no |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of a rapid multi-residue assay for detecting β-lactams using penicillin binding protein 2x*. | 2013-02 |
|
| [Determination of 9 cephalosporin drug residues in beef by ultra performance liquid chromatography-tandem mass spectrometry]. | 2009-07 |
|
| Effect of an intramammary teat seal and dry cow antibiotic in relation to dry period length on postpartum mastitis. | 2007-02 |
Patents
Sample Use Guides
1 syringe (250 mg) per quarter immediately after final milking.
Route of Administration:
Other
The activity of cefalonium against different bacterial strains was measured. The MIC90 values were: 0.125 ug/ml for Staphylococcus aureus, 0.0156 ug/ml for Streptococcus agalactiae, 0.0078 ug/ml for Streptococcus dysgalactiae, 0.06 ug/ml for Streptococcus uberis, 0.125 ug/ml for Arcanobacterium pyogenes, 2 ug/ml for Escherichia coli and Klebsiella spp.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
57519749
Created by
admin on Wed Apr 02 10:03:01 GMT 2025 , Edited by admin on Wed Apr 02 10:03:01 GMT 2025
|
PRIMARY | |||
|
1385046-35-4
Created by
admin on Wed Apr 02 10:03:01 GMT 2025 , Edited by admin on Wed Apr 02 10:03:01 GMT 2025
|
PRIMARY | |||
|
300000023691
Created by
admin on Wed Apr 02 10:03:01 GMT 2025 , Edited by admin on Wed Apr 02 10:03:01 GMT 2025
|
PRIMARY | |||
|
GMV4EAL4T7
Created by
admin on Wed Apr 02 10:03:01 GMT 2025 , Edited by admin on Wed Apr 02 10:03:01 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
